---
title: "BUZZ-Organon rises as review finds no issues in past biosimilar purchases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276443728.md"
datetime: "2026-02-20T12:57:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276443728.md)
  - [en](https://longbridge.com/en/news/276443728.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276443728.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276443728.md) | [繁體中文](https://longbridge.com/zh-HK/news/276443728.md)


# BUZZ-Organon rises as review finds no issues in past biosimilar purchases

Shares of healthcare firm Organon (OGN.N) rise 3.5% to $7.78 premarket

Co says an independent review found no wrongdoing in how it recorded earlier purchases of biosimilars, which are lower-cost versions of complex biologic drugs

Co says its board audit committee launched the review after concerns were raised about timing of past biosimilar purchases; review found no need to revise past SEC filings

Co says the annual report for 2025 will be filed on time

Shares down ~52% in 2025

### Related Stocks

- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [Organon & Co. (OGN.US)](https://longbridge.com/en/quote/OGN.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/en/news/281026919.md)
- [Teva receives FDA approval for Prolia biosimilar](https://longbridge.com/en/news/281172040.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md)
- [Io Biotech Inc - Files Voluntary Chapter 7 Bankruptcy Petition On March 31, 2026 - SEC Filing](https://longbridge.com/en/news/281187506.md)
- [Bourgeon Capital Management LLC Purchases 5,000 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/281678278.md)